Sao Tome and PrincipeTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.014 (<0.01–0.019) 7.3 (4.8–10)
Mortality (HIV+TB only) <0.01 (<0.01–0.01) 2.7 (0.86–5.5)
Prevalence  (includes HIV+TB) 0.21 (0.098–0.36) 111 (52–191)
Incidence  (includes HIV+TB) 0.18 (0.16–0.2) 97 (85–109)
Incidence (HIV+TB only) 0.038 (0.033–0.042) 20 (18–23)
         
Case detection, all forms (%) 87 (78–99)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 88 (47–100)
MDR-TB cases among notified pulmonary
TB cases
2 (0–4) 16 (9–18)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 70   9
Pulmonary, clinically diagnosed 50   9
Extrapulmonary 20   0
       
Total new and relapse 158    
Previously treated, excluding relapses      
Total cases notified 158    
Among 158 new and relapse cases:
11 (7%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 (7%) 2 (11%) 7
Laboratory-confirmed RR-/MDR-TB cases     2
Patients started on MDR-TB treatment ***     2
TB/HIV 2014 Number (%)
TB patients with known HIV status 158 (100)
HIV-positive TB patients 28 (18)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 28 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 28 (100)
HIV-positive people screened for TB 150  
HIV-positive people provided with IPT 0  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (73) 147
Previously treated cases, excluding relapse, registered in 2013   0
HIV-positive TB cases, all types, registered in 2013 (60) 30
RR-/MDR-TB cases started on second-line treatment in 2012 (80) 5
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 4.3
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 1.9
% Funded domestically <1%
% Funded internationally 40%
% Unfunded 59%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-09 Data: www.who.int/tb/data